EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Assessment of evidence for the off-label application of osteoanabolic drugs in fracture healing and spinal fusion

Hiroshi Kawaguchi

Journal of Bone and Mineral Metabolism · 2025

DOI: 10.1007/s00774-025-01589-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Bone and Mineral Metabolism, 2025. Verfasst von Hiroshi Kawaguchi. Beteiligte Einrichtung: Nadogaya Hospital, Shin-Kashiwa, Kashiwa, Chiba, 277-0084, Japan. kawaguchi0126@gmail.com. Hauptthemen laut MEDLINE: Spinal Fusion, Off-Label Use, Fracture Healing, Bone Density Conservation Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoanabolic drugs are sometimes prescribed off-label for "fracture healing and spinal fusion." This study examines the scientific validity of such practices by analyzing existing clinical reports. The purported bone union-promoting effect of teriparatide in fracture cases has been refuted in clinical trials. While teriparatide shows efficacy in accelerating spinal fusion after surgery for patients with osteoporosis, there is no scientific justification for its off-label use in patients without osteoporosis. For osteoporosis patients, no clear evidence suggests that teriparatide is superior to antiresorptive drugs, making the rationale for switching from antiresorptive drugs to teriparatide weak. The efficacy in postoperative spinal fusion may primarily be attributed to systemic improvements in bone quality and quantity, enhancing the mechanical engagement of implants. The clinical evidence for the off-label use of romosozumab, another osteoanabolic drug, in fracture healing and spinal fusion is insufficient to support its efficacy. In conclusion, osteoanabolic drugs, like antiresorptive drugs, primarily have systemic functions in osteoporosis patients, with limited evidence supporting their role in promoting localized bone formation in fractures or spinal fusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal FusionOff-Label UseFracture HealingBone Density Conservation AgentsHumansTeriparatideOsteoporosis

Stichwörter der Autor:innen

Fracture healingOff-label applicationOsteoanabolic drugOsteoporosisRomosozumabSpinal fusionTeriparatide

Substanzen

Bone Density Conservation AgentsTeriparatide

Autor:innen und Institutionen

  • Nadogaya Hospital, Shin-Kashiwa, Kashiwa, Chiba, 277-0084, Japan. kawaguchi0126@gmail.com.

Zitieren

APA

Kawaguchi, H. (2025). Assessment of evidence for the off-label application of osteoanabolic drugs in fracture healing and spinal fusion. Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-025-01589-9

Vancouver

Kawaguchi H. Assessment of evidence for the off-label application of osteoanabolic drugs in fracture healing and spinal fusion. Journal of Bone and Mineral Metabolism. 2025. doi:10.1007/s00774-025-01589-9

BibTeX
@article{Kawaguchi2025,
  author = {Kawaguchi, Hiroshi},
  title = {Assessment of evidence for the off-label application of osteoanabolic drugs in fracture healing and spinal fusion},
  journal = {Journal of Bone and Mineral Metabolism},
  year = {2025},
  doi = {10.1007/s00774-025-01589-9}
}
Kostenlos starten →